描述
Theralizumab is a humanized anti-CD28 monoclonal antibody designed for treating autoimmune diseases and cancer. After the first human trial, it was withdrawn due to severe toxicity (likely due to lymphopenia and human cytokine release).[A216527,A216532]
一般参考文献
Weissmuller S, Kronhart S, Kreuz D, Schnierle B, Kalinke U, Kirberg J, Hanschmann KM, Waibler Z: TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model. PLoS One. 2016 Mar 9;11(3):e0149093. doi: 10.1371/journal.pone.0149093. eCollection 2016.
Authors unspecified: Can super-antibody drugs be tamed? Nature. 2006 Apr 13;440(7086):855-6. doi: 10.1038/440855a.
分类
description:
direct-parent:Peptides
kingdom:Organic Compounds
superclass:Organic Acids
class:Carboxylic Acids and Derivatives
subclass:Amino Acids, Peptides, and Analogues
种类
Amino Acids, Peptides, and Proteins
D000602
Antibodies
D000906
Antibodies, Monoclonal
D000911
Blood Proteins
D001798
Globulins
D005916
Immunoglobulins
D007136
Immunoproteins
D007162
Proteins
D011506
Serum Globulins
D012712
同义词
language:english; code:; name;CD28-SuperMAB
language:english; code:; name;Theralizumab
受影响的生物体
Humans and other mammals
resource：Wikipedia
identifier：Theralizumab